THE PATHO-PHYSIOLOGY OF HYPERCALCEMIA

THE PATHO-PHYSIOLOGY OF HYPERCALCEMIA

There are many causes of hypercalcaemia, all of which are characterised by abnormalities in the transport of calcium across gut, bone, kidney or a combination of these. It is possible to separate the relative importance of these factors in individual patients which not only help the clinician to und...

Full description

Bibliographic Details
Main Authors:	Kanis, J, Cundy, T, Heynen, G, Russell, R
Format:	Journal article
Language:	English
Published:	1980

Similar Items

Ion channels in patho-physiology.
by: Trebak, M, et al.
Published: (2012)

The patho-aetiology of hip osteoarthritis
by: Thomas, G
Published: (2014)

The patho-anatomy of patellofemoral subluxation.
by: Monk, A, et al.
Published: (2011)

Mechanical induction of a delayed union in sheep - A model for investigations of the patho-physiological healing cascade in bone
by: Schell, H, et al.
Published: (2008)

Robotic right ventricle is a biohybrid platform that simulates right ventricular function in (patho)physiological conditions and intervention
by: Singh, Manisha, et al.
Published: (2024)

Osteomalacia in renal disease.
by: Kanis, J, et al.
Published: (1980)

VITAMIN-D IN CHRONIC RENAL-FAILURE
by: Kanis, J, et al.
Published: (1979)

VITAMIN-DS, MINERALS AND RENAL BONE-DISEASE
by: Kanis, J, et al.
Published: (1979)

God, being, pathos: Abraham Joshua Heschel's theological rejoinder to Heidegger
by: Herskowitz, D
Published: (2018)

GNA11 variants identified in patients with hypercalcemia or hypocalcemia
by: Howles, S, et al.
Published: (2023)

Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man?
by: Kanis, J, et al.
Published: (1978)

Pathos as a communicative strategy for online knowledge dissemination:the case of TED talks
by: Giuseppina Scotto Di Carlo,
Published: (2015)

The role of rhetoric in crowdfunding success: effects of logos, ethos, pathos and kairos appeals
by: Yew, David
Published: (2024)

Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations
by: Howles, S, et al.
Published: (2016)

Cinacalcet rectifies hypercalcemia in a patient with familial hypocalciuric hypercalcemia type 2 (FHH2) caused by a germline loss‐of‐function Gα11 mutation
by: Gorvin, C, et al.
Published: (2017)

Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia.
by: Nesbit, M, et al.
Published: (2013)

Cinacalcet corrects hypercalcemia in mice with an inactivating Gα11 mutation
by: Howles, S, et al.
Published: (2017)

Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism.
by: Pearce, S, et al.
Published: (1995)

Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3
by: Nesbit, M, et al.
Published: (2013)

Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3.
by: Nesbit, M, et al.
Published: (2013)

Physiological and therapeutic differences between vitamin D, its metabolites and analogues
by: Kanis, J, et al.
Published: (1977)

CALCITONINS ROLE - REPLY
by: Kanis, J, et al.
Published: (1977)

CALCITONIN, BONE-DISEASE, AND CHRONIC RENAL-FAILURE
by: Cundy, T, et al.
Published: (1978)

Cinacalcet reverses short QT Interval in familial hypocalciuric hypercalcemia type 1
by: Cuny, T, et al.
Published: (2023)

Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses.
by: Kanis, J, et al.
Published: (1979)

Physiological and therapeutic differences between vitamin D, its metabolites and analogues.
by: Kanis, J, et al.
Published: (1977)

Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13.
by: Lloyd, SE, et al.
Published: (1999)

THERAPEUTIC ADVANTAGE OF 1-ALPHA-HYDROXYLATED COMPOUNDS OVER VITAMIN-D
by: Kanis, J, et al.
Published: (1977)

EVIDENCE THAT ENDOGENOUS CALCITONIN PROTECTS AGAINST RENAL BONE-DISEASE
by: Heynen, G, et al.
Published: (1976)

The possible role of calcitonin deficiency in the development of bone disease due to chronic renal failure.
by: Kanis, J, et al.
Published: (1977)

EVIDENCE FOR A DIRECT EFFECT OF 24,25-DIHYDROXYCHOLECALCIFEROL ON INTESTINAL-ABSORPTION OF CALCIUM
by: Cundy, T, et al.
Published: (1978)

LINKAGE STUDIES IN A KINDRED WITH HYPOCALCIURIC HYPERCALCEMIA AND INCREASING SERUM PARATHYROID-HORMONE LEVELS INDICATE GENETIC-HETEROGENEITY
by: Trump, D, et al.
Published: (1993)

Neonatal hypocalcemic seizures in offspring of a mother with familial hypocalciuric hypercalcemia type 1 (FHH1)
by: Dharmaraj, P, et al.
Published: (2020)

Genetic mapping studies of familial benign hypercalcemia type 3 (FBH3) on chromosome 19q13.
by: Cianferotti, L, et al.
Published: (1999)

Effects of vitamin D metabolites and analogues on renal function.
by: Naik, R, et al.
Published: (1981)

Familial hypocalciuric hypercalcemia type 1 and autosomal-dominant hypocalcemia type 1: prevalence in a large healthcare population
by: Dershem, R, et al.
Published: (2020)

Effects of 24,25-dihydroxy-vitamin D3 on its plasma level in man.
by: Kanis, J, et al.
Published: (1981)

Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
by: Kanis, J, et al.
Published: (1977)

Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
by: Kanis, J, et al.
Published: (1977)

BIOLOGICAL EFFECTS OF 1,24,25-TRIHYDROXYVITAMIN-D3 IN MAN
by: Cundy, T, et al.
Published: (1979)